Analysts’ Top Healthcare Picks: Thermo Fisher (TMO), Eli Lilly & Co (LLY)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Thermo Fisher (TMO) and Eli Lilly & Co (LLY) with bullish sentiments.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Thermo Fisher (TMO)
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Thermo Fisher. The company’s shares closed last Tuesday at $488.64.
According to TipRanks.com, Ryskin is a 3-star analyst with an average return of
Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $668.73, implying a 37.1% upside from current levels. In a report issued on March 24, TipRanks – Google also upgraded the stock to Buy with a $526.00 price target.
See the top stocks recommended by analysts >>
Eli Lilly & Co (LLY)
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Eli Lilly & Co today. The company’s shares closed last Tuesday at $919.00.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $1250.11, implying a 39.9% upside from current levels. In a report issued on March 20, TipRanks – xAI also upgraded the stock to Buy with a $1019.00 price target.
Read More on TMO:
Disclaimer & DisclosureReport an Issue
- Thermo Fisher initiated with a Buy at DZ Bank
- Thermo Fisher Scientific: Early Clario Close Enhances 2026 Growth Outlook and AI-Driven Competitive Position, Supporting Buy Rating
- Thermo Fisher Completes Strategic Acquisition of Clario Holdings
- Thermo Fisher completes acquisition of Clario Holdings for $8.875B in cash
- Rising helium prices could create headwind for Bruker, says Jefferies
